| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 71930-0018-52 | 71930-0018 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 6, 2020 | In Use | |
| 68151-2959-06 | 68151-2959 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | 0.5 mg/1 | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Apr 18, 2005 | In Use | |
| 00085-3004-04 | 00085-3004 | Temozolomide | Temodar | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
| 71335-1628-05 | 71335-1628 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 28, 2022 | In Use | |
| 60505-3817-03 | 60505-3817 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 63187-0636-01 | 63187-0636 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 4, 2018 | In Use | |
| 59572-0402-00 | 59572-0402 | Lenalidomide | Revlimid | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 9, 2012 | In Use | |
| 00480-9257-08 | 00480-9257 | Octreotide Acetate | Octreotide Acetate | 1.667 mg/ml | Hormonal Therapy | Somatostatin Analog | Intramuscular | Mar 20, 2025 | In Use | ||
| 50633-0220-04 | 50633-0220 | Uridine triacetate | VISTOGARD | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 31, 2024 | In Use | |
| 62175-0242-19 | 62175-0242 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 10, 2016 | In Use | |
| 68001-0544-41 | 68001-0544 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 1, 2022 | In Use | |
| 69097-0398-78 | 69097-0398 | Paclitaxel protein-bound particles | Paclitaxel protein-bound particles | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Apr 15, 2025 | In Use | |
| 52959-0547-30 | 52959-0547 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 28, 1983 | In Use | |
| 71288-0103-20 | 71288-0103 | Bendamustine HCl | Bendamustine | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jun 5, 2023 | In Use | |
| 15054-1060-04 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sep 1, 2019 | In Use | ||
| 55700-0203-18 | 55700-0203 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 16, 2015 | No Longer Used | |
| 00069-0292-01 | 00069-0292 | filgrastim-aafi | Nivestym | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
| 63187-0709-20 | 63187-0709 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 1, 2016 | In Use | |
| 68788-9670-05 | 68788-9670 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 24, 2013 | In Use | |
| 71288-0129-02 | 71288-0129 | Dactinomycin | Dactinomycin | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Nov 13, 2020 | In Use | |
| 00185-7400-14 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 6, 2011 | In Use | ||
| 63187-0526-15 | 63187-0526 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 1, 2016 | In Use | |
| 42747-0761-01 | 42747-0761 | mogamulizumab-kpkc | POTELIGEO | 4.0 mg/mL | Immunotherapy | Monoclonal Antibody | CCR4 | Intravenous | Aug 8, 2018 | In Use | |
| 43598-0455-46 | 43598-0455 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 59651-0485-01 | 59651-0485 | PREDNISONE | PREDNISONE | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 28, 2022 | In Use |
Found 12159 results — Export these results
Home